A study to improve the resistance against Covid 19 illness with the help of Homoeopathic remedies.

Evaluating the immune boosting ability of a homoeopathic therapeutic strategy involving a nosode Tuberculinum 1M, followed by Zincum Metallicum 6C, Chininum Arsenicosum 6C and Calc Phos 6x in asymptomatic novel corona virus disease (Covid-19 illness) vulnerable risk group. - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/026045

Enrollment

800

Registered

2020-06-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Homoeopathic Medicines a therapeutic strategy consisting of Tuberculinum 1M followed by Zincum Metallicum 6C Chininum Arsenicosum 6C and Calc Phos 6x plus health monitoring: Known Homoe

Eligibility

Inclusion criteria

Inclusion criteria: 1. All existing co-morbidities. 2. High risk front line workers

Exclusion criteria

Exclusion criteria: 1.Those with end stage renal disease and progressive liver dysfunctions 2.Pregnant and lactating females 3.Anyone who has taken HCQS and / or Homoeopathic prophylaxis Ars alb 30 / any other similar medicines for boosting the immunity against Covid-19 illness

Design outcomes

Primary

Measure	Time frame
There will be a difference in the incidence rate of Covid-19 between control and intervention group. Incidence rate will be assessed with the help of RT PCR Covid-19 test. Patients in both the groups will be monitored for development of symptoms related to Covid-19. Timepoint: Subjects from both group will undergo evaluation on day 0, Day 15, day 30, day 45 and day 60 on predetermined parameters. Over and above these time points the patient will be provided with a help line and a physician for reporting symptoms on any given date.	—

Measure

Time frame

There will be a difference in the incidence rate of Covid-19 between control and intervention group. Incidence rate will be assessed with the help of RT PCR Covid-19 test. Patients in both the groups will be monitored for development of symptoms related to Covid-19. Timepoint: Subjects from both group will undergo evaluation on day 0, Day 15, day 30, day 45 and day 60 on predetermined parameters. Over and above these time points the patient will be provided with a help line and a physician for reporting symptoms on any given date.

—

Secondary

Measure	Time frame
There will be a difference in the number of patients developing symptoms of Covid-19 illness between control and intervention group.Timepoint: Subjects from both group will undergo evaluation on day 0, Day 15, day 30, day 45 and day 60 on predetermined parameters The predetermined parameters are 1. Fever 2. Myalgia 3. Malaise 4. Arthralgia 5. Headache 6. Confusion 7. Diarrhea 8. Vomiting 9. Dry cough 10. Cough with Sputum 11. Rhinorrhoea 12. Sore throat 13. Dyspnea 14. Chest pain 15. Alteration of taste and smell 16. Chills 17. Rigors 18. RT PCR Covid 19 test	—

Measure

Time frame

There will be a difference in the number of patients developing symptoms of Covid-19 illness between control and intervention group.Timepoint: Subjects from both group will undergo evaluation on day 0, Day 15, day 30, day 45 and day 60 on predetermined parameters The predetermined parameters are 1. Fever 2. Myalgia 3. Malaise 4. Arthralgia 5. Headache 6. Confusion 7. Diarrhea 8. Vomiting 9. Dry cough 10. Cough with Sputum 11. Rhinorrhoea 12. Sore throat 13. Dyspnea 14. Chest pain 15. Alteration of taste and smell 16. Chills 17. Rigors 18. RT PCR Covid 19 test

—

Countries

India

Contacts

Public ContactDr M K Kamath

Father Muller Homoeopathic Medical College, Mangalore

dr.dilip.dixit@gmail.com9757247179

Outcome results